SCHEMBL12013115

SCHEMBL12013115

CC1(C)C(=O)N([C@H]2C3CC4CC2C[C@](C)(C4)C3)N1c1ccccc1O

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 5/20 0.35
HSD11B1 P28845 5/20 0.32
KDM4E B2RXH2 2/20 0.31
ALDH1A1 P00352 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
TSHR P16473 1/20 0.31
ALOX12 P18054 1/20 0.31
HTT P42858 1/20 0.31
ATM Q13315 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
HSD17B10 Q99714 1/20 0.31
HTR7 P34969 1/20 0.31
POLB P06746 1/20 0.31
GAA P10253 1/20 0.31
EPHX2 P34913 1/20 0.30
PSMB5 P28074 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12012569 0.89 HSD11B1 (0.42) CNR2HSD11B1
SCHEMBL2170151 0.89 HSD11B1 (0.42) CNR2HSD11B1
SCHEMBL12012581 0.89 HSD11B1 (0.42) CNR2HSD11B1
SCHEMBL2169106 0.89 HSD11B1 (0.42) CNR2HSD11B1
SCHEMBL2169099 0.89 HSD11B1 (0.42) CNR2HSD11B1
SCHEMBL2168687 0.88 CNR2 (0.34) CNR2HSD11B1HTR7
SCHEMBL12012590 0.88 CNR2 (0.34) CNR2HSD11B1HTR7
SCHEMBL2168685 0.88 CNR2 (0.34) CNR2HSD11B1HTR7
SCHEMBL2169773 0.87 EPHX2 (0.38) CNR2HSD11B1KDM4EALDH1A1MAPT
SCHEMBL12013052 0.86 HSD11B1 (0.42) HSD11B1ALDH1A1HTTATMHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8252781-B2 1,2-diazetidin-3-one derivatives and drugs containing same KOWA COMPANY, LTD. (JP) 2012-08-28 US disclosed
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME KOWA COMPANY, LTD. (JP) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144694-A1 1,2-DIAZETIDIN-3-ONE DERIVATIVES AND DRUGS CONTAINING SAME HSD11B1, HSD11B2, HSD3B1 CNR2 2317/4885HSD11B1 1/4885KDM4E 4000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.